

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6226540

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
SALVACION CACATIAN	06/26/2020
DAVID A. CLAREMON	06/16/2020
CHENGGUO DONG	06/26/2020
YI FAN	06/16/2020
LANQI JIA	06/20/2020
STEPHEN D. LOTESTA	06/16/2020
SURESH B. SINGH	06/16/2020
SHANKAR VENKATRAMAN	06/17/2020
JING YUAN	06/18/2020
YAJUN ZHENG	06/16/2020
LINGHANG ZHUANG	06/18/2020

**RECEIVING PARTY DATA**

<b>Name:</b>	VITAE PHARMACEUTICALS, INC.
<b>Street Address:</b>	5 GIRALDA FARMS
<b>City:</b>	MADISON
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07940

**PROPERTY NUMBERS Total: 1**

Property Type	Number
<b>Application Number:</b>	16333852

**CORRESPONDENCE DATA****Fax Number:** (202)842-7899*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** (212) 479-6656**Email:** zippatentdocketingmailbox@cooley.com**Correspondent Name:** COOLEY LLP, ATTN: PATENT GROUP**Address Line 1:** 1299 PENNSYLVANIA AVENUE, NW**Address Line 2:** SUITE 700**Address Line 4:** WASHINGTON, D.C. 20004

PATENT

<b>ATTORNEY DOCKET NUMBER:</b>	SYND-703N01US 327830-2305
<b>NAME OF SUBMITTER:</b>	ERIC A. OWENS
<b>SIGNATURE:</b>	/Eric A. Owens/
<b>DATE SIGNED:</b>	07/30/2020

**Total Attachments: 10**

source=SYND-703-N01US\_Assignment#page1.tif  
source=SYND-703-N01US\_Assignment#page2.tif  
source=SYND-703-N01US\_Assignment#page3.tif  
source=SYND-703-N01US\_Assignment#page4.tif  
source=SYND-703-N01US\_Assignment#page5.tif  
source=SYND-703-N01US\_Assignment#page6.tif  
source=SYND-703-N01US\_Assignment#page7.tif  
source=SYND-703-N01US\_Assignment#page8.tif  
source=SYND-703-N01US\_Assignment#page9.tif  
source=SYND-703-N01US\_Assignment#page10.tif

Attorney Docket No. SYND-703/N01US 327830-2305

ASSIGNMENT

Salvacion CACATIAN, residing at 169 Front Street, Conshohocken, PA 19428; David A. CLAREMON, residing at 1508 Aidenn Lair Road, Maple Glen, PA 19002; Chengguo DONG, residing at 96 Arthur Avenue, Staten Island, NY 10305; Yi FAN, residing at 40 Bittersweet Drive, Doylestown, PA 18901; Lanqi JIA, residing at 22 Beaver Hill Road, Horsham, PA 19044; Stephen D. LOTESTA, residing at 99 Jennifer Lane, Burlington, NJ 08016; Suresh B. SINGH, residing at 4 Adams Road, Kendall Park, NJ 08824; Shankar VENKATRAMAN, residing at 114 Country Lane, Lansdale, PA 19446; Jing YUAN, residing at 537 Candlemaker Way, Lansdale, PA 19446; Yajun ZHENG, residing at 605 Giffin Court, Hockessin, DE 19707; and Linghang ZHUANG, residing at 3135 Fox Drive, Chalfont, PA 18914 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **INHIBITORS OF THE MENIN-MLL INTERACTION**, and which is a:

- (1)  provisional application
  - (a)  to be filed herewith; or
  - (b)  bearing Application No. , and filed on ;
  
- (2)  non-provisional application
  - (a)  to be filed herewith; or
  - (b)  bearing Application No. **16/333,852**, and filed on **March 15, 2019**; and/or
  
- (3)  PCT application
  - (a)  bearing Application No. **PCT/US17/51780**, and filed on **September 15, 2017**.  
  
and/or
  
- (4)  attached hereto.

**WHEREAS, Vitae Pharmaceuticals, Inc.**, a having its principal place of business at 5 Giralda Farms, Madison, NJ 07940, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements

of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

**NOW, THEREFORE**, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

(a) the Invention(s);

(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

6/26/2020

Date

DocuSigned by:  
*Salvacion Cacatian*  
8734C1756E8A41C  
Salvacion Cacatian

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/16/2020

Date

DocuSigned by:  
*David Claremon*  
5A522C89738041E  
David A. Claremon

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/26/2020

Date

DocuSigned by:  
*Chengguo Dong*  
FAC13DF2A85A4EA  
Chengguo Dong

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/16/2020

Date

DocuSigned by:  
*Yi Fan*  
16F14F6A8FB7346A  
Yi Fan

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/20/2020

Date

DocuSigned by:

*Lanqi Jia*

953A856A2ED48C

Lanqi Jia

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/16/2020

Date

DocuSigned by:

*Stephen Lotesta*

1AF0313E335E408

Stephen D. Lotesta

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name



6/16/2020

Date

DocuSigned by:  
*Suresh Singh*  
411786E4937E499...  
Suresh B. Singh

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/17/2020

Date

DocuSigned by:  
*Shankar Venkatraman*  
DE16F7FFB92742C...  
Shankar Venkatraman

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/18/2020

Date

DocuSigned by:

Jing Yuan

42CCE8E784C4CA

Jing Yuan

Witness:

Signature

Date

Printed Name

Witness:

Signature

Date

Printed Name

6/16/2020

Date

DocuSigned by:

Yajun Zheng

DSF74507F2754CA

Yajun Zheng

Witness:

Signature

Date

Printed Name

Witness:


Signature

Date

Printed Name

6/18/2020

Date

DocuSigned by:  
  
 5176F3548CE0486...  
 Linghang Zhuang

Witness:

Signature

Date

Printed Name

Witness:

Signature


Date

Printed Name

Attorney Docket No.: SYND-703/N01US 327830-2305

For and on behalf of ASSIGNEE:

Date: JULY 29, 2020

By: 


Name:

Title: Assistant Secretary

Company: ~~Vitae Pharmaceuticals, Inc.~~ *Jane*

On behalf of Vitae Pharmaceuticals, LLC *7/29/20*  
formally known as Vitae Pharmaceuticals, Inc.


Witness:

  
Signature

7/29/2020  
Date

Janet K. Stanczak  
Printed name

Witness:

  
Signature

7/29/2020  
Date

EILEEN R. KAMINSKI  
Printed name